Stanford Cancer Institute
Stanford MEDICINE

Stanford Cancer Institute

Genitourinary

Version Date:
January 9, 2023

Bladder

Localized Disease

- MIBC
  - Bladder Saving
    - **BLDR0041**
      Phase III TAR-200 in Combination with Cetrelimab vs Concurrent Chemoradiotherapy in Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
      .
      PI: Khaki
      Sponsor: Janssen Research & Development, LLC
  - Neoadjuvant
    - Cisplatin Ineligible
      - **BLDR0035**
        Phase Ib/II Umbrella Study Evaluating Multiple Immunotherapy-Based Treatments & Combinations in Urothelial Carcinoma (MORPHEUS-UC)
        PI: Srinivas
        Sponsor: Genentech, Inc. or F. Hoffmann-La Roche Ltd.
    - Cisplatin Eligible
      - **BLDR0037**
        Phase III Enfortumab Vedotin + Pembrolizumab vs Gemcitabine & Cisplatin in Muscle-invasive Bladder Cancer
        PI: Srinivas
        Sponsor: Merck Sharp & Dohme Corp.
- NIMBC Patients with Recurrent NMIBC
  - **BLDR0040**
    Phase I, Open-Label, Dose Escalation and Expansion Study of PF-07225570 Either Alone or in Combination with an Anti-PD-1 Antibody, In Participants with Recurrent Non-Invasive Bladder Cancer
    PI: Skinner
    Sponsor: Pfizer

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu